Pages that link to "Q39158096"
Jump to navigation
Jump to search
The following pages link to Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma (Q39158096):
Displaying 11 items.
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential (Q28075927) (← links)
- Psoriasis induced by thalidomide in a patient with multiple myeloma (Q33833466) (← links)
- Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow (Q35834665) (← links)
- Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma (Q36413655) (← links)
- Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels (Q37325843) (← links)
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma (Q38896657) (← links)
- In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. (Q38968027) (← links)
- Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK. (Q42111039) (← links)
- The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells. (Q42923841) (← links)
- Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. (Q45756098) (← links)
- Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma (Q50197484) (← links)